[Indigenous and imported low molecular weight heparin in the treatment of chronic hepatitis B and cirrhosis with hepatitis B virus: a prospective randomized controlled clinical study].

Objective: To evaluate the effect of indigenous and imported low molecular weight heparin (LMWH) in the treatment of chronic hepatitis and hepatic cirrhosis aiming at seeking a safe and effective anti-fibrosis therapy.

Methods: A prospective randomized controlled clinical study of the treatment of patients with chronic hepatitis B using indigenous and imported LMWH was performed. Seventy-five patients were randomly divided into three groups: conventional treatment group (n=15), conventional treatment plus imported LMWH treatment group (n=30) and conventional treatment plus indigenous LMWH treatment group (n=30). The clinical parameters and treatment results in three groups were compared.

Results: Three weeks after treatment, Child-Pugh scores in LMWH treatment groups were significantly lower than that in conventional treatment group (all P<0.05), hepatic function, serum PIII P and type IV collagen levels and portal vein blood flow velocity were much better (all P<0.05), levels of serum prealbumin were significantly elevated (all P<0.05). There were no significant differences between two groups with LMWH treatment. Subcutaneous hemorrhage, incidence of hematoma was lower (10.0% vs. 33.3%, P<0.05), area of ecchymosis was smaller [(0.004 2+/-0.012 7) cm(2) vs. (0.01 64+/-0.027 8) cm(2), P<0.05], and pain was released (8.3% vs. 81.0%, P<0.05) in conventional treatment plus indigenous LMWH treatment group than in conventional treatment plus imported LMWH treatment group.

Conclusion: LMWH in combination with conventional treatment for patients with cirrhosis of liver, significantly improves the outcome, indigenous LMWH calcium is a safe and effective anti-fibrosis drug as imported LMWH, also the price is lower and pain is less intense during injection than the latter.